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1. Introduction
Breast cancer remains one of the commonest forms of 
cancer worldwide. Recent improvements in treatment 
regimens have resulted in substantial reductions in 
mortality, but there remains an urgent need to devise 
more accurate techniques to guide clinicians as to 
which therapies are needed for specific patients.
This is especially true for breast cancer patients 
with the estrogen receptor (ER) positive form of the 
disease. These constitute nearly 80% of all cases and 
require clinicians to decide whether there is additional 
benefit from cytotoxic chemotherapy when added to 
endocrine therapy. In these cases, accurate grading 
is an especially important issue since often, in node-
negative breast cancer, the decision as to whether to 
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Abstract
The majority of cancers are diagnosed using excised biopsy specimens. These are graded, using 
a gold-standard histopathology protocol based on haemotoxylin and eosin (‘H  +  E’) chemical 
staining. However the grading is done by eye and if the same biopsy is graded by different 
practitioners, they typically only agree ~70% of the time.
The resulting overtreatment problem constitutes a massive unmet need worldwide.
Our new “Digistain” technology, uses mid-infrared imaging to map the fractional concentration 
of nucleic acids, i.e. the nuclear-to-cytoplasmic chemical ratio (NCR) across an unstained biopsy 
section. It allows a quantitative ‘Digistain index’ (DI) score, corresponding to the NCR, to be 
reproducibly extracted from an objective physical measurement of a cancer. Our objective here is 
to evaluate its potential for aiding cancer diagnosis for the first time. We correlate the DI scores with 
H  +  E grades in a double-blind clinical pilot trial.
Two adjacent slices were taken from 75 breast cancer FFPE blocks; one was graded with the 
standard H  +  E protocol, and also used to define a ‘region of interest’ (RoI). Digistain was then used 
to acquire a DI value averaged over the corresponding RoI on the other (unstained) slice and the 
results were statistically analysed.
We find the DI score correlates significantly (p  =  0.0007) with tumor grade in a way that promises 
to significantly reduce the inherent subjectivity and variability in biopsy grading.
The NCR is elevated by increased mitotic activity because cells divide when they are younger and, 
on average, become smaller as the disease progresses. Also, extra DNA and RNA is generated as the 
nuclear transcription machinery goes awry and nuclear pleomorphism occurs. Both effects make the 
NCR a recognized biomarker for a wide range of tumors, so we expect Digistain will find application 
in a very wide range of cancers.
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administer potentially harmful cytotoxic chemother-
apy rests to a great extent on grading.
Currently, hematoxylin and eosin (‘H  +  E’) stain-
ing is widely used for the histopathological diagnosis 
of cancer [1]. Biopsy specimens are processed into 
formalin-fixed-paraffin-embedded (FFPE) blocks. 
These are sectioned, by microtome, into slices usually 
a few microns thick, before being deparaffinised and 
H  +  E stained. Hematoxylin binds to the acidic cell 
components, primarily DNA and RNA, and dyes the 
nuclei blue, while the eosin dyes the cytoplasmic pro-
teins pink.
Typically the sections are graded subjectively by 
eye, using disease-specific grading protocols. Histo-
logical grading of breast cancer currently varies widely 
across multiple institutions and practitioners, because 
it relies on subjective criteria [2]. For example, analysis 
of  >24 000 biopsies, graded by 732 breast cancer grad-
ers, found that they only agreed ~73% of the time [3] 
on average.
The mid-infrared (mid-IR) part of the electro-
magnetic spectrum roughly spans wavelengths 
between λ ~ 2.5 µm and λ ~ 25 µm. Molecules absorb 
these wavelengths linearly, by exciting vibronic trans-
itions that are specific to their chemical bonds. In a 
large molecule each chemical moiety supports its 
own collection of localized vibrational modes, whose 
absorption wavelengths and strengths are well-known. 
These give so-called ‘fingerprint’ absorption peaks in 
the molecules’ mid-IR absorption spectra. IR chem-
ists have long used these, often in automated systems 
[4], to analyze the chemical compositions of unknown 
mixtures, and to quantify the concentrations of vari-
ous compounds in a mixture.
Digistain extends this idea by measuring the 
absorption of specially chosen mid-IR wavelengths [5] 
in a 2D image. The wavelengths that are chosen, λ ~ 
8 µm and λ ~ 6 µm, are absorbed as vibrational exci-
tations in the phosphate (nuclear) and amide (cyto-
plasmic) moieties, respectively, that are present in tis-
sue (section 2, Methods). This raw absorption data is 
processed to produce a spatial map of the ratio of these 
two chemical components, that is precise to the one 
percent level [6], across a tissue section.
A computer then generates a false-colour ‘digitally 
stained’ image from this [7] that presents both the 
morphological and the chemical information (figure 
1) in a visual form (section 2, Methods). This image 
then can be readily assimilated and used by histopa-
thology personnel, and it can also be directly com-
pared with the standard H  +  E images to augment the 
grading process.
A pathologist selects a ‘region of interest’ (RoI) by 
referencing the corresponding H  +  E slide, and the 
corresponding pixel values in the Digistain image of 
the tumor are averaged to generate a ‘DI score’, also 
precise to the percent level [6], which we then use to 
correlate with the clinical and histopathological data.
Here we report the results of an initial exploratory 
pilot trial, using archived FFPE blocks with follow up, 
aimed at identifying the diagnostic capability of this 
Digistain imaging technology in Breast Cancer.
2. Results
2.1. Patient characteristics
Table 1 shows the patient and disease characteristics. 
Patients were all female with ages ranging from 30.4 
to 83.7, mean age 58.7 at diagnosis. More than half of 
the sample had grade 2 tumors (54.3%). The majority 
were HER2 negative (90.0%). Initially there were 75 
patients in the sample. Four patients were recurrences 
and were excluded from the grading analysis.
2.2. Association between DI scores and tumor grade
Figure 2 shows the distribution of the DI score (section 
2, Methods) in the full sample of 75 patients. Also 
shown are the data subsets for those patients with and 
without 5 year follow up. The DI score has a reasonably 
Normal distribution with mean and median values 
slightly higher for those who died compared with 
those still alive at 5 years.
The full dataset was used to explore relationships 
between the potential prognostic variables. A sig-
nificant relationship between DI score and grade was 
observed (p  =  0.0007). No other significant relation-
ships were observed between the other potential prog-
nostic variables (table 2). Figure 3 shows that mean 
DI score increases with grade. The mean DI score for 
grade 1 patients is 0.58 (SD 0.08), the mean is increased 
to 0.61 (SD 0.07) for grade 2 patients and 0.68 (SD 
0.09) for grade 3 patients.
2.3. Association of DI score with survival time
One patient had no follow up information so is 
excluded from these analyses. Twenty-one patients 
had died at the time of follow up and 49 were censored. 
The median survival time had not been reached and 
the low number of deaths in the study resulted in wide 
confidence intervals around the hazard ratio, and 
the DI score alone did not significantly influence the 
survival time (p  =  0.19, Cox regression).
This is the first ever study of the value of the DI 
score in a clinical setting, and the DI index is a contin-
uous variable, so there is no a priori way of choosing 
an appropriate DI cut point for stratifying the sample 
into ‘low’ and ‘high’ risk survival groups. As a first 
effort, we employed the Contal O’Quigley method 
(section 1, Methods) as an unbiased way of identify-
ing the optimal DI cut point. The actual DI cut point 
value, (DI  =  0.668, p  =  0.20) returned by this analysis 
must be regarded only as preliminary, but neverthe-
less, using it in a log-rank test already suggests that 
Digistain can stratify significantly (p  =  0.02) for risk.
3. Discussion
In summary, this study shows that this new Digistain 
technology for mapping out the NCR, can measure 
the grade of a breast cancer biopsy objectively. 
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By processing and mapping the ratio of the 
concentration of the phosphate and amide moieties 
across the tissue section it is possible to generate an 
image. Direct comparison with the standard H  +  E 
images then allows a DI score to be produced, that 
summarizes the tumor NCR, and we find that this 
correlates very strongly with tumor grade.
The significance of the correlation (p  =  0.0007) 
observed here, in spite of the moderate N  =  71 sample 
size, argues that, already, Digistain could form a use-
ful adjunct to existing H  +  E Breast cancer grading. 
The grading scheme used in the NPI is 33% weighted 
to mitotic activity, and 33% weighted to nuclear pleo-
morphism. Both of these are likely to be strongly cor-
related with the NCR, and we believe this is the mech-
anism behind the correlation that we find here.
The significant (p  =  0.02) correlation with sur-
vival times is encouraging, and can be qualitatively 
explained by the same factors as the correlation with 
grade. However, since, this is the first and only time the 
DI score has been used in this way, independent trials 
will be needed to exclude the possibility of over fitting 
artefacts before an appropriate DI cut-point can be 
determined.
As seen in table 2, the significance of the correla-
tion between grade and DI is rather greater than that 
between DI and many of the objective variables that 
are already used in diagnosis. This argues that aug-
menting the current subjective grading protocol with 
the DI information is likely to reduce overall diag-
nostic variability.
This new Digistain technique uses routinely pro-
cessed, unstained paraffin sections of cancer tissue, 
and it images and quantifies the NCR chemical marker 
within minutes. The test can be performed by unskilled 
personnel, with a single mouse click, and, the image 
information it generates can be stored, transmitted 
and analysed (including using ‘big data’ techniques) 
all in the digital domain.
These DI values come from specimens that are col-
lected and prepared in a way that is already established 
and respected by the clinical profession. The majority 
of the overall clinical testing process that is needed is 
already part of the existing ‘gold standard’ H  +  E 
‘standard operating procedure’ (SOP), so it is already 
accepted, approved and budgeted for.
The Digistain process adds no extra patient proce-
dures to existing cancer diagnosis schemes, and it fits 
well with existing pathology laboratory workflows. As 
in this study, it can be conveniently evaluated post hoc, 
using a wide range of cancer samples that are already 
readily available in the form of archived FFPE blocks. 
This offers a route to clinical acceptance that has a min-
imum of cost and ethical implications.
The Digistain technology is label-free, and it uses 
low radiation intensities and photon-energies that are 
harmless to both the operator and the sample. The imag-
ing machine requires only a 13A mains supply and a 
30  ×  30 cm bench top footprint. Future trials may allow 
the grading process to be partially or fully automated, 
especially since the DI images are already in a digital for-
mat that is compatible with machine-vision methods.
Constraining the data to only 4 pre-selected 
wavelengths saves time because only useable data is 
acquired, and the simplicity of the data processing 
means that we can test and understand the diagnostic 
value of the image data with confidence.
In addition, it should be noted that, because of 
the controlled and objective nature of the imaging 
measurement, the DI pixel values are absolute values 
that are directly relatable to the NCR. Since the NCR 
itself is a known cancer biomarker [8–10] this implies 
that the individual pixel values themselves could carry 
diagnostic (or even prognostic) value, over and above 
the morphology information in the image. This ‘abso-
lute value’ feature is highly unusual in the field of bio-
medical imaging and it offers new avenues for future 
machine vision image analysis.
Figure 1. Comparison of (a) H  +  E stained and (b) Digistain images of a typical Breast biopsy section. In this Digistain false colour 
rendering, the areas of cancer cells appear green.
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Finally, we note that pleomorphism and mitotic 
activity changes are common to a range of cancers, 
and we believe that that future studies will reveal that 
the technology has both a diagnostic and a prognostic 
capability that has the potential to impact across a very 
wide spectrum of diseases and conditions that are cur-
rently assessed by histopathology.
4. Methods
4.1. Statistical methods
No formal sample size calculation was carried out for 
this, the first pilot trial of the Digistain technology. 
Samples were drawn from an audited collection of 
randomly selected breast cancer biopsy tissue blocks 
on the basis of available histological material and 
Table 1. Patient and disease characteristics. 70 patients 
included in the study were female aged 30–84 years. 83% of the 
tumours were invasive ductal carcinoma (IDC) type. Grade 
corresponds to tumour grade. HER2, PgR and ER refer to 
human epidermal growth factor receptor, progestorone receptor 
and estrogen receptor statuses, respectively. 66% of the patients 
were LN  +  (lymph node positive). One patient opted out of 
surgery. A Digistain index (DI) was recorded for each patient.
Gender
  Female N (%) 70 (100%)
Age (N  =  70)
  Mean age (SD) 58.7 (13.0)
  Median age (range) 58.5 (30.4–83.7)
Grade, N (%)
  1 12 (17.1%)
  2 38 (54.3%)
  3 20 (28.6%)
ER, N (%)
  Negative 8 (11.4%)
  Positive 61 (87.1%)
  Unknown 1 (1.4%)
PgR, N (%)
  Negative 19 (27.1%)
  Positive 50 (71.4%)
  Unknown 1 (1.4%)
HER2, N (%)
  Negative 63 (90.0%)
  Positive 6 (8.6%)
  Unknown 1 (1.4%)
LN status, N (%)
  0 46 (65.7%)
  1 11 (15.7%)
  2 9 (12.9%)
  3 4 (5.7%)
IDC, N (%)
  No 12 (16.9%)
  Yes 58 (82.9%)
Surgery_y/n, N (%)
  No 1 (1.4%)
  Yes 69 (98.6%)
Digistain index (N  =  70)
Mean DI (SD) 0.62 (0.08)
Median DI (range) 0.61 (0.47–0.89)
Figure 2. (a) Distribution of the DI score in the full sample 
of 75 patients (b) Sub-distributions for those patients with 
(N  =  41) and without (N  =  29) 5 year follow up (c) the sub-
distributions for those who died (N  =  49) compared with 
those still alive (N  =  21) at 5 years.
Table 2. Relationships between DI score and potential prognostic 
factors.
Variable
p-value for relation-
ship with DI score
Tumour size 0.79
Grade 0.0007
IDC (yes or no) 0.18
Ln status 0.73
HER2 status 0.50
PgR 0.46
Er 0.3149
Age 0.80
Surgery (yes or no) 0.74
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patient follow up data. The clinical samples were de-
identified and obtained without individual consent 
under a protocol approved by the Charing Cross 
Hospital Institutional Review Board.The tissue blocks 
comprised of biopsies collected between 1999–2003. 
The cohort of patients were all female and treated at 
a single hospital and aged between 30–85 years at time 
of surgery. 79% of patients were alive and 22% had 
relapsed during last follow up.
Patient and disease characteristics are summarized 
descriptively. The DI score is summarized descriptively 
using mean, median, standard deviation, range for the 
overall sample and for each grade. Boxplots are used to 
visualize these data. The association of grade with DI 
score is explored using linear regression.
Kaplan–Meier curves (not shown) were used to 
visualise the length of survival and censoring in the 
patient sample. Cox regression was used to explore the 
association of DI score with survival time. The Con-
tal and O’Quigley method was used to explore if a cut 
point for DI score could be found that was able to sepa-
rate the survival curves into a high and low risk group.
The work here is reported in accordance with 
the REMARK checklist [11] for prognostic marker 
studies.
4.2. Measuring the DI scores
Clinical samples were de-identified and two adjacent 
sections, each ~3 µm thick, were cut from each 
FFPE block; one was H  +  E stained and graded, as 
usual, under the Elston–Ellis method as used in the 
Nottingham prognostic index (NPI) system.
It was also used by the histopathologist to visually 
delineate a RoI, which corresponded to the most sig-
nificant grade of tissue in the section, i.e. the region 
in the tumour with the highest cellularity. The second 
section was mounted on an IR transmitting CaF2 slide, 
then it was de-paraffinised using the same process as 
defined in the standard bio bank H  +  E staining SOP.
The Digistain imager uses bespoke software to reg-
ister the H  +  E image with the Digistain one, before 
acquiring the DI score for the section by averaging the 
DI values of the pixels corresponding to the tissue in 
the RoI.
The Digistain imager [4] operates with an ~11 µm 
effective pixel size and takes pictures, in transmission, 
of the tissue section in wavelength bands specified by 
4 IR interference filters. One filter records an image at 
the λ ~ 6.06 µm peak from the N–H ‘amide 1’ absorp-
tion, and a second records an image at a nearby wave-
length, (λ ~ 6.23 µm) to serve as a background. The 4 
images are accurately registered, and subtracting these 
two signals at a pixel-by-pixel level gives a value that 
is proportional to the concentration of N–H moieties 
in that part of the section. Repeating the process with 
mid-IR filters centered at λ ~ 8.13 µm and λ ~ 8.50 µm 
gives a measure of the areal concentration of the phos-
phodiester moiety.
The N–H and PO−2  moieties are mainly present in 
the cytoplasmic proteins and nuclear DNA backbone, 
respectively, so these two images could, in principle, be 
used to computer generate the pink and blue comp-
onents in a qualitative digital analogue of conventional 
H  +  E image. However, ‘Digistain’ goes on to use a 
proprietary procedure [7] to generate a quantitative 
pixel value, the so-called DI value that corresponds to 
the absolute ratio of the phosphodiester to the amide 
concentrations at that point in the section. The ratio-
ing protocol is designed to produce a repeatable DI in a 
way that is robust against technical factors such as non-
uniformities in illumination and detector sensitivity, 
thermal background radiation, and section thickness 
[4].
The DI measures the concentration ratios of phos-
phodiester to amide moieties, and because these are 
dominantly related to the amounts of nuclear and 
cytoplasmic material, respectively [4], the DI images 
can be regarded as 2D maps of the nuclear-to-cyto-
plasmic ratio, (NCR).
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